This segment focuses on the clinical implications of the SERENA-6 trial and its evaluation of circulating tumor DNA–guided treatment switching in hormone receptor–positive, HER2-negative metastatic breast cancer. Dr. Adam Brufsky introduces the trial within the context of ongoing regulatory and clinical debate regarding biomarker-driven intervention prior to radiographic progression.
This segment examines real-world access and reimbursement considerations influencing the use of oral selective estrogen receptor degraders in hormone receptor–positive, HER2-negative metastatic breast cancer.
This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.
This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
